Discounted Cash Flow (DCF) Analysis Levered

Meridian Bioscience, Inc. (VIVO)

$32.91

+0.20 (+0.61%)
All numbers are in Millions, Currency in USD
Stock DCF: 97.69 | 32.91 | undervalue

Free Cash Flow

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 200.77213.57201.01253.67317.90359.23405.94458.72518.37585.77
Revenue (%)
Operating Cash Flow 41.3534.7835.8347.9866.8768.0176.8586.8498.13110.89
Operating Cash Flow (%)
Capital Expenditure -4.47-4.20-3.80-3.30-18.31-9.44-10.67-12.06-13.62-15.40
Capital Expenditure (%)
Free Cash Flow 36.8930.5832.0344.6848.5558.5666.1874.7884.5195.50

Weighted Average Cost Of Capital

Share price $ 32.91
Beta 0.276
Diluted Shares Outstanding 44.01
Cost of Debt
Tax Rate 21.05
After-tax Cost of Debt 2.25%
Risk-Free Rate
Market Risk Premium
Cost of Equity 4.092
Total Debt 65.92
Total Equity 1,448.43
Total Capital 1,514.36
Debt Weighting 4.35
Equity Weighting 95.65
Wacc

Build Up Free Cash Flow

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 200.77213.57201.01253.67317.90359.23405.94458.72518.37585.77
Operating Cash Flow 41.3534.7835.8347.9866.8768.0176.8586.8498.13110.89
Capital Expenditure -4.47-4.20-3.80-3.30-18.31-9.44-10.67-12.06-13.62-15.40
Free Cash Flow 36.8930.5832.0344.6848.5558.5666.1874.7884.5195.50
WACC
PV LFCF 54.1458.8263.9069.4375.43
SUM PV LFCF 334.61

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 4.01
Free cash flow (t + 1) 97.41
Terminal Value 4,846.11
Present Value of Terminal Value 3,981.23

Intrinsic Value

Enterprise Value 4,315.84
Net Debt 16.15
Equity Value 4,299.69
Shares Outstanding 44.01
Equity Value Per Share 97.69